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Abstract
Background—Genetic predisposition to life-threatening cardiac arrhythmias such as in
congenital long-QT syndrome (LQTS) and catecholaminergic polymorphic ventricular tachycardia
(CPVT) represent treatable causes of sudden cardiac death in young adults and children. Recently,
mutations in calmodulin (CALM1, CALM2) have been associated with severe forms of LQTS and
CPVT, with life-threatening arrhythmias occurring very early in life. Additional mutation-positive
cases are needed to discern genotype-phenotype correlations associated with calmodulin
mutations.
Methods and Results—We employed conventional and next-generation sequencing
approaches including exome analysis in genotype-negative LQTS probands. We identified five
novel de novo missense mutations in CALM2 in three subjects with LQTS (p.N98S, p.N98I,
p.D134H) and two subjects with clinical features of both LQTS and CPVT (p.D132E, p.Q136P).
Age of onset of major symptoms (syncope or cardiac arrest) ranged from 1–9 years. Three of five
probands had cardiac arrest and one of these subjects did not survive. Although all probands had
LQTS, two subjects also exhibited electrocardiographic features consistent with CPVT. The
clinical severity among subjects in this series was generally less than that originally reported for
CALM1 and CALM2 associated with recurrent cardiac arrest during infancy. Four of five probands
responded to β-blocker therapy whereas one subject with mutation p.Q136P died suddenly during
exertion despite this treatment. Mutations affect conserved residues located within calcium
binding loops III (p.N98S, p.N98I) or IV (p.D132E, p.D134H, p.Q136P) and caused reduced
calcium binding affinity.
Conclusions—CALM2 mutations can be associated with LQTS and with overlapping features of
LQTS and CPVT.
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Introduction
Congenital long QT syndrome (LQTS) is a recognizable and treatable genetic predisposition
to sudden cardiac death in children and young adults.1 Considerable genetic heterogeneity
underlies this syndrome, although a large fraction of successfully genotyped LQTS subjects
belong to three major subtypes (LQT1, LQT2, and LQT3) associated with mutations in three
genes encoding plasma membrane ion channels (KCNQ1, KCNH2, and SCN5A,
respectively). Distinct genotype-specific patterns of T-wave morphology,2,3 triggers for
cardiac events,4 clinical outcomes5 and response to the epinephrine provocation test6,7 have
been observed. Importantly, genotype can also influence the response to specific drug
therapy.8–11 Genetic testing for known arrhythmia susceptibility genes has become standard-
of-care for some disorders including LQTS, but despite the rapid progress in understanding
the genetic basis, an etiology remains unknown in many cases.12 Additional studies are
needed to reveal the missing heritable factors and to elucidate genotype-phenotype
correlations.
Recently, mutations in two of three genes encoding identical peptide sequences for the
essential calcium signaling protein calmodulin were associated with life-threatening
arrhythmia predisposition including malignant forms of LQTS, catecholaminergic
polymorphic ventricular tachycardia (CPVT) and idiopathic ventricular tachycardia
(IVF).13–15 Nyegaard and colleagues identified two distinct missense CALM1 (p.N54I,
p.N98S) mutations in association with CPVT.13 Crotti, et al. used exome sequencing and
targeted re-sequencing to discover novel CALM1 (p.D130G, p.F142L) and CALM2
(p.D96V) missense mutations in subjects with infantile or perinatal presentations of severe
LQTS associated with recurrent cardiac arrest.14 Most recently, Marsman and colleagues
identified a novel CALM1 mutation (F90L) segregating with IVF and sudden death in a
Moroccan family.15 Although this limited number of calmodulin mutations suggests
preliminary genotype-phenotype correlations, additional mutations are needed to establish
the spectrum of clinical features and severity of arrhythmia phenotypes associated with
calmodulin mutations.
Here we report the discovery of five novel de novo missense CALM2 mutations associated
with congenital arrhythmia susceptibility in probands of varying ancestry. The mutations
alter conserved residues that directly coordinate calcium ions in the carboxyl-terminal
domain of calmodulin and cause significant reductions in calcium binding affinity. Clinical
and electrophysiological findings in these subjects suggested that CALM2 mutations can be
associated with less severe forms of LQTS compared to our previous report14 as well as
with overlapping clinical features of LQTS and CPVT.
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Methods
Study subjects
The QT interval was corrected for heart rate using Bazett’s formula (QTc = QT/√RR), and
the diagnosis of LQTS was made by the Schwartz criteria.1 All individuals who participated
in the study gave written informed consent prior to genetic and clinical investigations in
accordance with the standards of the Declaration of Helsinki and the local ethics committees
at each participating institution. We studied two Japanese cohorts including one consisting
of 12 unrelated LQTS subjects who were without a genetic diagnosis after sequencing genes
previously associated with life-threatening arrhythmias (KCNQ1, KCNH2, SCN5A, SCN1B,
SCN2B, SCN3B, SCN4B, KCNE1, KCNE2, KCNJ2 and CAV3),13,14,16 and another cohort
consisting of 190 unrelated LQTS patients in whom whole exome sequencing was
performed. Exome sequencing was performed on a parent-child trio in which the proband
was a child who suffered cardiac arrest at age 17 months. A German mutation-negative
LQTS proband and a Moroccan girl with sudden cardiac death were also screened for
mutations in CALM1, CALM2 and CALM3.
Candidate gene and exome sequencing
Targeted exon capture was performed for 240 candidate arrhythmia susceptibility genes
(Supplemental Table S1) using the SureSelect Target Enrichment System according to the
manufacturer’s suggestions (Agilent Technologies, Inc. Santa Clara, CA). The captured
DNA was sequenced on the Genome Analyzer IIx platform (Illumina Inc. San Diego, CA)
with paired-end reads of 101 base pairs (bp) for insert libraries consisting of 150–200 bp
fragments. On average for targeted capture sequencing, 1.1 Gbp of short read sequence data
were generated and 98.9% were mapped to the reference human genome. Whole exome
capture was performed using Agilent SureSelect Human All Exon V4 reagent and captured
DNA was sequenced on Illumina HiSeq2000 (performed at RIKEN) or HiSeq2500
(performed at Vanderbilt University) platforms. For data obtained on the HiSeq2000, an
average of 6.4 Gbp of short read sequence data were generated with 98.6% mapped
successfully to the reference human genome and 66-fold average coverage for all capture
exons. For data obtained on the HiSeq2500, an average of 5.8 Gbp was generated per
subject with 99.8% mapped and 50-fold average coverage.
Sequence data analysis
Sequence reads were mapped to the human reference genome (GRCh37) using the Burrows-
Wheeler Aligner (BWA: version 0.6.1).17 Possible duplicate reads were removed using
SAMtools18 and custom software leaving an average of 0.8 Gb and 5.5 Gb for targeted
capture and exome sequencing, respectively. More than 93% of targeted regions were
covered by at least 10 reads. After filtering by pair mapping distance, mapping uniqueness
and orientation between paired reads, the mapping result files were converted into the pileup
format using SAMtools.18 Variant calling was conducted in part on the basis of published
methods.19–21 We, further, used the following quality control filters: (i) alignments near
putative indels were refined using GATK,22 and (ii) a strand bias filter excluded variants
whose alternative allele was preferentially found on one of the two available read
orientations at the site. Variants found in dbSNP Build 137, 1000 Genomes,23 or Exome
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Variant Server (EVS)24 databases were excluded from further analyses. Synonymous and
intronic (other than canonical splice sites) variants were also excluded. Three other exome
databases (RIKEN database of 731 non-cardiac disease Japanese exomes, Human Genetic
Variation Browser [HGVD] database including exome data obtained from 1208 Japanese
subjects [http://www.genome.med.kyoto-u.ac.jp/SnpDB] and the Institute of Human
Genetics Helmholtz Zentrum München database of >3,000 exomes of European ancestry)
were also queried for the candidate mutations.
Additional mutation detection
Targeted PCR-Sanger sequencing was performed as described previously14 on DNA from a
German female with clinical features of LQTS and CPVT, as well as in a Moroccan girl
with sudden cardiac death and a presumptive diagnosis of CPVT to search for variants in the
coding exons of CALM1, CALM2, and CALM3. Variants discovered by exome sequencing
were also confirmed by Sanger sequencing using an automated capillary electrophoresis
DNA sequencing platform (Applied Biosystems, Foster City, CA), then further annotated
based upon evolutionary amino acid conservation (Mutation Taster)25 and predicted impact
on protein function (Polyphen2, SIFT).26,27 Mutation position in calmodulin was based
upon RefSeq NP_001734 counting the predicted translational start codon (Met) as position
1.
Expression of recombinant calmodulins and measurement of calcium affinity
Biochemical studies of recombinant calmodulin proteins were performed as previously
described.14 Briefly, recombinant wildtype and mutant calmodulins were expressed in E.
coli and purified by standard chromatographic approaches. Macroscopic affinity constants
for calcium binding in the amino-terminal and carboxy-terminal domains were determined
by measuring changes in intrinsic fluorescence as reported by Shea and coworkers.28,29 The
data were analyzed by plotting the normalized fluorescence signal vs free Ca2+
concentration and fitting to a two-site Adair function for each domain.30,31
Results
Case presentations
Case 1—A 6-year-old Japanese girl was admitted to the hospital for evaluation of syncope
and a markedly prolonged QT interval. She had a history of fetal bradycardia but had an
uneventful birth. She had her first episode of syncope at age 19 months. An
electrocardiogram (ECG) at that time showed marked QT prolongation (QTc = 579 ms) with
atypical notched, late peaking T waves (Fig. 1A). Atrial pacing at 100 bpm prolonged QTc
from 596 ms to 619 ms, whereas mexiletine shortened QTc from 596 ms to 550 ms (Fig.
1B). Subsequently, she experienced multiple episodes of cardiac arrest during exertion when
she failed to take mexiletine prompting placement of an implantable cardioverter
defibrillator (ICD) at age 14 years. Medical therapy with mexiletine and a β-adrenergic
receptor blocker atenolol was generally effective in preventing ventricular arrhythmias,
although there was an episode of appropriate ICD discharge that occurred during exertion.
The patient had no history of seizures or developmental delay. Genetic testing for mutations
in KCNQ1, KCNH2, SCN5A, SCN1B, SCN2B, SCN3B, SCN4B, KCNE1, KCNE2, KCNJ2
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and CAV3 was negative. There was no family history of LQTS or sudden death, and both
parents had normal QTc intervals (father 369 ms, mother 394 ms) as did her two brothers
(368, 388 ms).
Case 2—A 5-year-old Japanese boy had an episode of syncope with seizure while running.
Two months later, he had a similar episode and was evaluated in an emergency room. An
ECG exhibited QTc prolongation (478 ms, Fig. 2A), whereas an echocardiogram,
electroencephalogram, and brain magnetic resonance imaging were normal. He showed no
developmental delay. There was no family history of arrhythmias or sudden death, and both
parents (father 364 ms, mother 396 ms) and his brother (340 ms) had normal QTc intervals.
Epinephrine infusion test did not induce ectopic beats but caused marked QTc prolongation
(baseline HR/QT/QTc, 56 bpm/484 ms/466 ms; peak HR/QT/QTc, 94 bpm/446 ms/558 ms;
steady-state HR/QT/QTc, 73 bpm/484 ms/535 ms; Fig. 2B). This subject did not tolerate
exercise testing because of dizziness. Genetic testing for mutations in KCNQ1, KCNH2,
SCN5A, KCNE1, KCNE2, KCNJ2 and AKAP9 was negative. Treatment with propranolol
alone or in combination with mexiletine shortened the QTc interval to 471 – 473 ms (Fig.
2C), but he continued to experience syncope and dizziness while running. The drugs were
replaced with metoprolol at age 11 years. Subsequently, he had no further episodes of
syncope, and there was normalization of the QTc (449 ms) with elimination of the notch in
the descending limb of the T wave (Fig. 2C).
Case 3—A 29 year-old German female, who was previously diagnosed with perinatal
bradycardia and neonatal LQTS, had been treated with pindolol. Her family history was
negative for cardiac arrest and sudden death. On β-blocker therapy she remained
asymptomatic until age 9 years when she suffered syncope while swimming following an
interruption of therapy. At that time, there was evidence of exercise-induced polymorphic
ventricular ectopy. She became asymptomatic for several years after resumption of
treatment with various β-blockers (pindolol, propranolol, atenolol). Her resting ECG
exhibited QT prolongation (465 – 578 ms) with persistent biphasic T waves in leads III,
aVF, aVL, V3 and negative T waves in V4-V6 (Fig. 3A). The patient never suffered
seizures, and she had normal physical and mental development. At age 22 years, exercise-
induced polymorphic ventricular ectopy and one 3-beat run of polymorphic ventricular
tachycardia was documented (Fig. 3B, Supplemental Fig. S1). Echocardiographic evaluation
was normal, but MRI revealed features consistent with non-compaction of the left ventricle
myocardium (LVNC). Both parents had normal QTc intervals (father 407 ms, mother 377
ms) with no signs of polymorphic ventricular arrhythmias. Directed screening of genes
involved with LQTS and CPVT (KCNQ1, KCNH2, SCN5A, KCNE1, KCNE2, KCNJ2,
ANK2, CAV3, KCNE3, SNTA1, RYR2, CASQ2) was negative for mutations.
Case 4—A Moroccan female from a family with no history of cardiac arrhythmia was
hospitalized at age 8 years after an episode of syncope associated with prolonged period of
unconsciousness. At that time, she had a prolonged QTc interval (500 ms) with ventricular
bigeminy. A Holter recording demonstrated prolonged QTc interval (ECG images were not
available). Echocardiographic evaluation was normal. Both parents and four female siblings
were asymptomatic. The subject was treated with nadolol (40 mg/day) and she remained
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asymptomatic with QTc intervals ranging from 420 – 450 ms without ventricular ectopy.
Unfortunately, she died suddenly in at age 11 years while dancing at a wedding in Morocco.
The initial diagnosis was LQTS, and later a diagnosis of catecholaminergic polymorphic
ventricular tachycardia was considered due to clinical circumstances and ventricular ectopy.
No exercise stress test was performed. No neurologic dysfunction was reported and a head
CT scan was normal. Genetic testing was negative for KCNQ1, KCNH2, SCN5A, KCNE1,
RYR2, CASQ2, and TRDN.
Case 5—A previously healthy Caucasian boy from England suffered cardiac arrest
secondary to ventricular fibrillation at age 17 months and he was promptly resuscitated.
Electrocardiogram showed bradycardia and a prolonged QTc interval (555 ms; Fig. 4).
There was no family history of cardiac arrhythmia and both parents were healthy with
normal QTc interval duration. There were no siblings. An ICD was placed soon after the
cardiac arrest and no discharges were documented over the ensuing 13 months. The subject
was also treated with β-blockers. Genetic testing for mutations KCNQ1, KCNH2, SCN5A,
KCNE1 and KCNE2 was negative.
A summary of clinical features observed in the five cases is presented in Table 1.
Discovery of novel CALM2 mutations
To identify mutations in candidate arrhythmia susceptibility genes, a custom targeted exon
capture probe panel interrogating 240 genes (Supplemental Table S1) was used to screen 12
unrelated mutation-negative Japanese LQTS probands using a next generation sequencing
platform resulting in an average 187-fold coverage of targeted regions (additional details of
the method will be reported elsewhere). A heterozygous nonsynonymous single nucleotide
variant (c.400G>C, Fig. 5A) in exon 5 of CALM2 was identified in a 6 year old girl
(described above as Case 1). The nucleotide change predicts the substitution of a conserved
aspartic acid residue with histidine (p.D134H) within the fourth EF-hand calcium-binding
motif in the C-terminal domain of the encoded calmodulin protein. The location of this
variant within the protein was four residues away from a mutation (p.D130G) previously
associated with a very severe form of infantile LQTS (Fig. 5B,C).14 This variant was not
found in her parents nor her two brothers, and is absent in dbSNP, 1000 Genomes, Exome
Variant Server (EVS), RIKEN and HGVD exome databases consistent with a novel de novo
mutation.
Motivated by this finding, we searched for other calmodulin gene (CALM1, CALM2,
CALM3) mutations in exome sequence data (coverage was 35X, 92X and 59X for the three
calmodulin genes, respectively) obtained from 190 unrelated mutation-negative Japanese
LQTS probands. A second heterozygous nonsynonymous variant (c.293A>G, Fig. 5A) was
found in CALM2 exon 5 in a 5-year-old boy (described above as Case 2) diagnosed with
LQTS. This variant is predicted to replace a conserved asparagine at position 98 with serine
(p.N98S) within the third EF-hand calcium-binding motif in calmodulin (Fig. 5B,C).
Interestingly, de novo p.N98S mutation in a different calmodulin gene (CALM1) was
previously associated with CPVT in an Iraqi female without QT prolongation.13 This variant
was not found in his parents or brother, and was absent in exome data of the other 189
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LQTS probands as well as in databases of genetic variation (dbSNP, 1000 Genomes, EVS,
RIKEN and HGVD exome databases) consistent with a de novo missense mutation. The
probability that two private non-synonymous mutations occurred in CALM2 among 190
Japanese samples by chance was estimated as 0.0258 (see Supplemental Material).
Exome sequencing was also performed on a 17 month old English boy who suffered cardiac
arrest in the context of LQTS (Case 5) and his healthy parents (coverage averaged 30X for
the three calmodulin genes). After excluding all variants shared with at least one parent,
synonymous variants and common variants, the proband was found to have de novo
nonsynonymous variants in 4 protein-coding genes (CALM2, OBSCN, DLG1, GOLGA3).
However, only the variant identified in CALM2 (c.A293>T, Fig. 5A) predicting substitution
of asparagine at position 98 in calmodulin with isoleucine (p.N98I, Fig. 5B,C) was predicted
to be ‘deleterious’ by SIFT and ‘probably damaging’ by PolyPhen-2. This variant occurs at
the same position as the CALM2 mutation discovered in Case 2 (LQTS) and a previous
reported CALM1 mutation (N98S) found in a child with CPVT.13 CALM2-p.N98I was
absent in the previously mentioned databases.
By candidate gene screening of CALM1, CALM2 and CALM3, we identified two other
heterozygous missense CALM2 variants. One variant was discovered in a 29-year-old
German female who was diagnosed initially with neonatal LQTS and later exhibited
exercise-induced polymorphic ventricular ectopy (Case 3). The variant (c.396T>G, Fig. 5A)
predicted the replacement of a conserved aspartic acid residue at position 132 with
glutamate (p.D132E) within the fourth EF-hand calcium-binding motif in calmodulin (Fig.
5B,C). The location of the variant is two amino acids N-terminal of p.D134H (Case 1), and
two residues C-terminal of the previously identified p.D130G.14 This variant was predicted
to be damaging by SIFT and Mutation Taster, while it was predicted to be benign by
Polyphen2. The mutation was not found in the aforementioned databases of genetic variants
(dbSNP, 1000 Genomes, EVS) and was also absent in the Helmholtz exome database in
which mean coverage of CALM2 was greater than 95-fold.14 The variant was not found in
her parents and therefore D132E was considered a likely novel de novo missense CALM2
mutation.
The second CALM2 variant discovered by targeted sequencing was found in an 8 year old
Moroccan girl (Case 4) with presumptive diagnoses of LQTS and CPVT who died suddenly
during exertion despite ongoing treatment with β-blockers. The variant (c.A407>C, Fig. 5A)
predicted the replacement of glutamine at position 136 with proline (p.Q136P) in the fourth
EF-hand calcium-binding motif (Fig. 5B,C). The mutation was not found in the
aforementioned databases of genetic variants (dbSNP, 1000 Genomes, EVS), and was
absent in the parents and four siblings consistent with a de novo mutation.
CALM2 mutations confer impaired calcium affinity
We previously demonstrated that calmodulin mutations associated with early onset LQTS
confer reduced affinity for calcium.14 Similarly, Nyegaard and colleagues examined calcium
affinity for CALM1 p.N98S, which they observed in a de novo case of CPVT, and found a
slight depression in C-domain calcium binding affinity.13 To determine the biochemical
consequences of the four novel CALM2 mutations we identified, recombinant calmodulin
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proteins were generated and purified, and in vitro Ca2+ binding affinities were measured.
None of the four mutations significantly affected Ca2+ affinity in the N-domain, but
substantial effects on affinity in the C-domain were observed (Fig. 6). Dissociation constants
for Ca2+ (Kd) of 2.1 ± 0.1, 15 ± 1, 48 ± 10, 27 ± 5 and 19 ± 2 μM, were determined for
wildtype, N98I, D132E, D134H and Q136P, respectively, corresponding to a 7 to 23-fold
reduction in Ca2+ binding affinity to the C-domain. These data demonstrate a significant
functional impairment caused by the novel calmodulin variants consistent with disease-
causing mutations that will likely disrupt the ability to transduce intracellular Ca2+ signals
leading to cardiac arrhythmia susceptibility.
Discussion
The identification of new arrhythmia susceptibility genes and mutations will facilitate the
prevention of sudden cardiac death through the rapid identification of at-risk populations,
and may illuminate new molecular targets for therapy. Here we expand the spectrum of
mutations in calmodulin, a recently demonstrated cause of life-threatening heart rhythm
disorders.
Calmodulin functions as a Ca2+ sensor in a wide range of intracellular Ca2+ signaling
pathways. The protein sequence is completely conserved among all vertebrates, and in
humans three unique genes (CALM1, CALM2, CALM3) encode for identical calmodulin
protein.32 In the recent reports of human calmodulin gene mutations, there was only one
CALM2 allele identified compared to five CALM1 mutations.13–15 The previously identified
calmodulin mutations associated with LQTS phenotypes along with those we report here
affect conserved residues within the two EF-hand motifs of the C-domain and cause
substantially impaired Ca2+ affinity. The mutations with the greatest impact on Ca2+ affinity
involve substitutions of conserved aspartic acid residues (D130G, D132E, D134H) known to
be directly involved in coordinating Ca2+ ions in Ca2+ binding loop IV.33,34 Notably, even
substitution with the highly similar glutamic acid side chain in D132E has an influence on
Ca2+ affinity. Similar effects of this subtle Asp to Glu mutation on the Ca2+ affinity of
calmodulin have been reported.35 Although a functional effect was not predicted in silico by
PolyPhen2, it is well established that each residue in the Ca2+ binding loops of calmodulin
and other EF-hand proteins contribute to the biochemical functions of the protein.36
The cellular mechanisms responsible for arrhythmia susceptibility in the setting of
calmodulin mutations are likely to be complex given the multitude of molecular interactions
possible for this critically important signaling molecule. As previously speculated for
LQTS,14 dysfunctional calmodulin may disrupt Ca2+ dependent inactivation of L-type
calcium channels leading to increased depolarizing current during the plateau phase of the
cardiac action potential. Impaired regulation of voltage-gated sodium channels may also be
evoked by certain LQTS-associated calmodulin mutations. For calmodulin mutations
associated with CPVT, aberrant regulation of the sarcoplasmic reticulum ryanodine
receptor/Ca2+ release channel (RYR2) is a plausible mechanism based on previous studies.37
Interestingly, the CPVT mutations do not impair Ca2+ affinity to the same extent as those
associated with LQTS.13 The molecular and cellular pathophysiology of arrhythmia
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susceptibility in the setting of calmodulin mutations is currently under intense
investigation.38–40
Our findings further expand the phenotypic spectrum of cardiac arrhythmias associated with
calmodulin mutations. Three of the probands (Cases 1, 2, 5) had a later onset of LQTS
compared to what was described in the study by Crotti, et al., in which calmodulin mutation-
positive subjects had highly malignant ventricular arrhythmias beginning very early in life.14
Further, none of the CALM2 mutation positive subjects we report here had significant
neurological findings, other than syncope-associated seizures (Case 1), in contrast to the
original report in which most subjects had seizures and/or developmental delays. The
previously observed neurological impairments were speculated to be the result of brain
injury secondary to hypoxia in the setting of recurrent cardiac arrest. The minimal or absent
neurological symptoms in the probands we describe here may reflect fewer episodes of
cardiac arrest or more rapid resuscitation. These new observations further imply that
neurological symptoms may not be an intrinsic manifestation of calmodulin mutations.
Genotype-phenotype correlations among the calmodulin mutation positive subjects we
described may provide clues to the pathophysiological mechanisms. In particular, CALM2-
p.D132E was identified in an adult with a history of neonatal LQTS who later developed
exercise-induced polymorphic ventricular arrhythmia consistent with CPVT. Similarly,
CALM2-p.Q136P was identified in a child with LQTS and ventricular ectopy somewhat
suggestive of CPVT. We speculate that the combined clinical features of LQTS and CPVT
reflect the impact of p.D132E and possibly p.Q136P on two principal molecular targets.
Abnormal calmodulin regulation of L-type Ca2+ channels would account for impaired
myocardial repolarization similar to Timothy syndrome,41 while dysregulation of RYR2
would lead to altered regulation of intracellular calcium homeostasis as expected in
CPVT.42,43
Our study also revealed that an identical amino acid substitution in two distinct calmodulin
genes can present with different clinical phenotypes. Whereas CALM1-p.N98S was
originally found in an Iraqi female with CPVT,13 we identified CALM2-p.N98S in a
Japanese male with an unambiguous LQTS phenotype (Case 2). The physiological basis for
this genotype-phenotype disparity is unknown, but may involve differences in the
corresponding proteomes of different probands due to sex or ethnicity, or differences in
regional or cell-type specific expression of CALM1 and CALM2.
Except during periods of medication non-compliance, all CALM2 mutation positive
probands described in this report were responsive to β-blockers administered alone or in
combination with mexiletine. However, because of recurrent cardiac arrests during treatment
lapses, Cases 1 and 5 had implantation of an ICD. In our prior report of calmodulin
mutations in severe LQTS, probands with de novo CALM1 or CALM2 mutations
experienced arrhythmia recurrence on pharmacological therapy and were eventually treated
with ICD implantation to reduce the risk for sudden cardiac death.14 Similarly, symptomatic
mutation-positive subjects with IVF reported by Marsman, et al., had ICD implantation.15
By contrast, the Swedish family segregating CPVT with mutation CALM1-N54I described
by Nyegaard, et al. exhibited variable responses to β-blockers alone and only 1 of 10 living
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mutation-positive subjects received an ICD.13 None of the cases we report here underwent
left cardiac sympathetic denervation.
In conclusion, we report discovery of five novel de novo CALM2 mutations in association
with LQTS and exertion-induced arrhythmias. The encoded mutant calmodulin proteins
have impaired C-domain Ca2+ binding affinity that will presumably cause dysfunction in
Ca2+ signaling with resulting adverse effects on plasma membrane ion channels,
intracellular membrane ion channels or possibly both. Therapy with β-blockers was
successful in preventing life-threatening exertion-triggered arrhythmias. Our study provides
new evidence of congenital arrhythmia susceptibility caused by calmodulin mutations,
provides further information regarding genotype-phenotype correlation and expands the
allelic diversity within CALM2. Calmodulin gene mutations should be sought in pediatric
cases of LQTS and CPVT for whom other genetic candidates have been excluded. Because
of the predominance of de novo mutations, calmodulin genes could be considered especially
when both parents are unaffected.
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Figure 1.
Electrocardiographic abnormalities in Case 1. A) Standard 12-lead ECG recorded at age 6
years showing marked QTc prolongation (579 ms) with atypical T wave morphology (late-
peaking with notch on the descending limb). B) Atrial pacing at 100 bpm prolonged QTc
from 596 ms to 610 ms. By contrast, mexiletine treatment shortened QT interval from 596
ms to 550 ms.
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Figure 2.
Electrocardiographic abnormalities in Case 2. A) Standard 12-lead ECG recorded at age 5
years showing QTc prolongation (478 ms). B) Epinephrine challenge test prolonged QTc at
peak (466 ms to 558 ms) and at steady-state (535 ms). C) Propranolol or propranolol with
mexieltine caused QTc shortening from 517 ms to 471 ms and 473 ms, respectively.
Metoprolol normalized the QTc to 449 ms.
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Figure 3.
Electrocardiographic features of Case 3. A) Standard 12-lead ECG recorded at age 27 years
showing QTc prolongation (567 ms). B) Polymorphic ventricular ectopy recorded (lead III)
during exercise (step test) at age 28 years. During exercise, a progressive increase of heart
rate was observed with no arrhythmias until 110 bpm was reached. A 3-beat episode of
polymorphic ventricular tachycardia was recorded at 113 bpm. A representative 12-lead
ECG during exercise is provided as Supplemental Fig. S1.
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Figure 4.
Electrocardiographic features of Case 5. Standard 12-lead ECG recorded at age 2 years
showing QTc prolongation (555 ms) and bradycardia (HR = 55 bpm) during β-blocker
treatment. Because of bradycardia, only one beat was recorded in the limb leads.
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Figure 5.
Novel de novo CALM2 mutations. A) Pedigrees and Sanger sequence electropherograms of
each proband (marked by arrow). QTc values for each individual are shown underneath the
corresponding pedigree symbol. B) Amino acid sequence alignments for calmodulins from
different species with location of the five missense mutations. Amino acid sequence of EF-
hands III and IV are underlined. C) Schematic model of Ca2+ binding loops in the N-
terminal (I and II) and C-terminal (III and IV) domains of calmodulin showing the locations
of mutations. Red circles represent the CALM2 mutations (p.N98S, p.N98I, p.D132E,
p.D134H, p.Q136P) identified in our present study, green symbols represents previously
reported mutations.
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Figure 6.
Impaired Ca2+ binding by mutant calmodulin C-domains. A) Representative Ca2+ titrations
monitored by intrinsic fluorescence for recombinant WT (black circles) and mutant
calmodulins (D132E, blue triangles; D134H, red squares). Kd values derived by fitting data
from three replicates to a two-site model were (mean ± SEM) 2.1 ± 0.1, 48 ± 10, and 27 ± 5
μM for wildtype, D132E and D134H, respectively. B) Representative Ca2+ titrations for WT
(black circles) and mutant (N98I, inverted orange triangles; Q136P, green diamonds)
calmodulins. Kd values derived by fitting data from three replicates to a two-site model were
(mean ± SEM) 2.3 ± 0.1, 19 ± 2, and 15 ± 1 μM for wildtype, N98I and Q136P,
respectively.
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